Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (237)	4/22/2009 10:42:28 AM
From: Arthur Radley	Respond to of 318

BJ...IMO the problem is that we are only getting Cappy's spin on this story. I find it hard to believe that the FDA would stop this drug from being approved when you consider the only option for an FDA approved drug. If the FDA has a drug approved that is made from 'mince meat' cow parts then impurity and consistency must be an issue that the FDA doesn't find a problem. However, it appears that DSCO "must" have a major problem with their manufacturing process. Bottomline........DSCO management is spinning a one-sided response. DSCO needs a partnership deal.....and it appears obvious that they can't find such, as they would have to show any partner the full data on all aspects of Surfaxin. I'm out of this stock and have no plans to buy back.......there is much need for this drug, but I don't think DSCO has the required resources, nor management savvy to get it done! All Just My Opinion!!! Good luck.. Take a look at MITI news today......looks encouraging!

To: Biotech Jim who wrote (237)	4/22/2009 11:43:39 AM
From: kenhott	1 Recommendation Respond to of 318

I have not listened to the CC because it is not near the top of my big stack. My thinking is that there is something fundamentally wrong with this drug/application in the eyes of the FDA instead of just someone at the FDA playing the bad guy. No matter how big an organization, people and their managers make the decisions. One strong opinion at the FDA can substantially influence a drug application. But the FDA is a fishbowl and no single person/small group can "get away with" doing this to DSCO at the agency without the reasons going up the management chain. I find it unlikely that the entire FDA organization is out to get DSCO. So I believe while people may find the FDA reasons to be not well balanced, for instance, DSCO is not going to win that type of argument at this point. I get to a conclusion that the problem is at DSCO and DSCO is probably stuck. Company is saying that the FDA not bringing new issues is a good thing. But the flip side of that is the FDA is not moving on the old issues and DSCO can't find the right answers.